High doses of a potential Alzheimer's vaccine cause significant side effects including build up of fluid in the brain but these effects are considerably reduced in lower doses, says new research.
Alzheimer's Society comment:
'With potential new therapies it is always important to weigh up the pros and cons. This latest evidence suggests that with the right dosage bapineuzumab could be relatively safe for people with dementia but we are still some way from knowing if it could be a viable Alzheimer's vaccine.
'Vaccine development is an important area for dementia research. If we can stop the symptoms before they affect day to day life, this could offer hope to millions of people.'
Dr Anne Corbett